Product Description
AT-007 is an investigational, novel Aldose Reductase Inhibitor (ARI) being developed for the treatment of several rare diseases.
Mechanisms of Action: AKR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - GalactosemiasOrphan Drug - Congenital Disorders of GlycosylationOrphan Drug - GalactosemiasOrphan Drug - SORD DeficiencyPriority Review - *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Applied Therapeutics
Company Location: NEW YORK NY 10017
Company CEO: Shoshana Shendelman
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: Czech Republic, Italy, United Kingdom, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Galactosemias|SORD Deficiency
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
AT-007-1005 | P3 |
Unknown Status |
SORD Deficiency |
2026-11-30 |
|
2022-000491-18 | P3 |
Active, not recruiting |
SORD Deficiency |
2026-01-14 |
|
AT-007-1002 | P3 |
Active, not recruiting |
Galactosemias |
2024-12-01 |
|
INSPIRE | P3 |
Active, not recruiting |
SORD Deficiency |
2024-07-31 |
66% |